Biblio

Export 10 results:
Filters: Author is Marie-France Demers  [Clear All Filters]
2020
Demers M-F, Fortier L, Corbeil O, Breault A-S, Roy M-A. Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use. Asian J Psychiatr. 2020;48:101541.
Corbeil O, Corbeil S, Giroux I, Jacques C, Dorval M, Demers M-F, Roy M-A. Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports. J Clin Psychopharmacol. 2020;40(2):191-194.
2019
Lachance A, Corbeil O, Corbeil S, Chalifour G, Breault A-S, Roy M-A, Demers M-F. Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence. J Clin Psychopharmacol. 2019;39(4):393-397.
2018
Roy M-A, Vallières C, Lehoux C, Leclerc L-D, Demers M-F, Achim AM. More intensive probing increases the detection of social anxiety disorders in schizophrenia. Psychiatry Res. 2018;268:358-360.
Roy M-A, Demers M-F, Achim AM. Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity. J Psychiatry Neurosci. 2018;43(4):287-288.
2017
Vincent PD, Demers M-F, Doyon-Kemp V, Duchesneau J, Halme A, Masson V. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophr Res. 2017;185:96-100.
2016
Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, Grignon S, Fleury M-J, Lesage A, Demers M-F, Roy M-A, Carrier J-D, Delorme A. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand. 2016;134(5):374-384.
2015
Roy M-A, Achim AM, Vallières C, Labbé A, Merette C, Maziade M, Demers M-F, Bouchard R-H. Comorbidity between anxiety disorders and recent-onset psychotic disorders. Schizophr Res. 2015;166(1-3):353-4.
2004
Alméras N, Després J-P, Villeneuve J, Demers M-F, Roy M-A, Cadrin C, Mottard J-P, Bouchard R-H. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004;65(4):557-64.
0
Carrier J-D, Blais L, Cohen A, Courteau J, Roberge P, Larouche A, Grignon S, Fleury M-J, Lesage A, Demers M-F, Roy M-A, Delorme A, Vanasse A. [Initiating an antipsychotic drug treatment for schizophrenia: the situation in Quebec, Canada, from 1998 to 2006]. Sante Ment Que. 42(1):85-103.